To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
BASF Increases Prices for Nature-Identical Carotenoids for Human and Animal Nutrition, Excluding Astaxanthin
BASF globally increases prices for all nature-identical carotinoid formulations containing canthaxanthin, citranaxanthin, C30-ester and beta-carotene by approximately 12%, effective immediately or as existing commitments allow.
The products affected are all grades for human and animal nutrition including Lucarotin®, Beta-Carotene, Lucantin® Red, Lucantin® Yellow and Lucantin® CX Forte. All existing contractual obligations will be honored. Lucantin® Pink (astaxanthin) is not affected.
This increase is necessary to compensate for negative impacts resulting from a combination of increased energy and raw material prices, higher logistics costs and negative exchange rate effects.
- 1Panspecific antibodies: Novimmune successful in multiple specificities
- 2Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 3Researchers Hone in on Stem Cell that Speeds Healing of Stubborn Diabetes Wounds
- 4Merck KGaA Acquires Bioscience Company in India
- 5Fresenius to acquire US drug-maker APP Pharmaceuticals in US$3.7 billion deal
- 6Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 7Olive oil: the key to curing cancer?
- 8Takara Bio to Acquire Clontech Unit of BD Biosciences
- 9Magnetic material attracts attention for cancer therapy
- 10Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement for the Development and Commercialization
- Network Filtering in Biobanks: Protective Protein against Huntington’s Disease Identified
- Novel regulator inhibits toxic protein aggregates in Huntington's disease
- Scientists X-ray anti-inflammatory drug candidates
- Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer
- Detecting lung cancer at an early stage